<DOC>
	<DOCNO>NCT01532336</DOCNO>
	<brief_summary>The purpose study evaluate clinical microbiological efficacy safety NVC-422 compare vehicle adenoviral conjunctivitis . Adults child one year age old diagnosis adenoviral conjunctivitis least one eye base upon positive adenovirus test result use Aden-Detactor Plus kit ( Rapid Pathogen Screening , Inc ) . Subjects randomly assign receive either NVC-422 Vehicle .</brief_summary>
	<brief_title>Efficacy Safety NVC-422 Treatment Adenoviral Conjunctivitis</brief_title>
	<detailed_description>This randomize ( 1:1 ) double-masked , vehicle-controlled , multi-center , parallel group study two treatment arm : NVC-422 Ophthalmic Solution 0.33 % ( `` NVC-422 '' ) NVC-422 Vehicle ( `` Vehicle '' ) . Subjects meet inclusion/exclusion criterion enrol study , randomize evaluate 6 visit : - Visit 1 : Screening , Day 1 - Visit 2 : Day 3 - Visit 3 : Day 6 - Visit 4 : Day 11 End Treatment ( EOT ) - Visit 5 : Day 18 Test-of-Cure ( TOC ) - Visit 6 : Day 42 Follow-up Subjects dose OU 10 day . Specimens collect OU visit quantitative PCR adenoviral load molecular typing .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Inclusion</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Signs symptom viral conjunctivitis least one eye 3 day less Bulbar conjunctival injection Other inclusion criterion per protocol Presence subepithelial infiltrates ( SEIs ) Day 1 visit either eye A suspected bacterial , fungal , herpes , Chlamydia Acanthamoeba coinfection , base clinical observation Other exclusion criterion per protocol</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>adenovirus</keyword>
	<keyword>conjunctivitis</keyword>
	<keyword>pinkeye</keyword>
</DOC>